Role of endogenous interferon gamma in murine tumor growth and tumor necrosis factor alpha antitumor efficacy

Annals of Surgical Oncology

Volumn 3, Issue 2, 1996, Pages 198-203

  Doherty, Gerard M ^a   Alexander, H Richard ^b   Merino, Maria J ^b   Venzon, David J ^b   Norton, Jeffrey A ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Interferon gamma; Mouse; Sarcoma; Tumor necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; C57BL MOUSE; FEMALE; IMMUNOLOGY; MORTALITY; MOUSE; PATHOLOGY; PHYSIOLOGY; SARCOMA; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; IMMUNOGLOBULINS; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030096769     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02305801     Document Type: Article

References (19)

1. Asher A, Mule JJ, Reichert CM, Shiloni A, Rosenberg SA. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987;138:963-74.
2. Blick M, Sherwin SA, Rosenblum M. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;47:2986.
3. Chapman PB, Lester TJ, Casper ES, et al. Phase I study of recombinant tumor necrosis factor (rTNF). Proc ASCO 1986;5:231.
4. Khan A, Pardue A, Aleman C, et al. Phase I clinical trial with recombinant tumor necrosis factor (TNF). Proc ASCO 1986;5:226.
5. Fraker DL. Biologic therapy with tumor necrosis factor- - clinical applications by systemic and regional administration. In: Rosenberg SA, ed. Biological therapy of cancer. Philadelphia, PA: JB Lippincott, 1994.
6. Lienard D, Ewalenko P, Delmotti JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in com-bination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
7. Fraker DL, Alexander HR. The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and practice of oncology updates. Philadelphia, PA: JB Lippincott, 1993:1-10.
8. Billiau A. Gamma-interferon: the match that lights the fire? Immunol Today 1988;9:37-40.
9. Talmadge JE, Bowersox O, Tribble H, Shepard M, Liggitt D. Therapeutic and toxic activity of tumor necrosis factor is synergistic with gamma interferon. Pathol Immunopathol Res 1989;8:21-34.
10. Brouckaert PGG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 1986;38:763-9.
11. Mutch DG, Massad LS, Kao M-S, Collins JL. Proliferative and antiproliferative effects of interferon-gamma and tumor necrosis factor-α on cell lines derived from cervical and ovarian malignancies. Am J Obstet Gynecol 1990;163: 1920-4.
12. Doherty GM, Lange JR, Alexander HR, Langstein HN, Buresh CM, Norton JA. Evidence for interferon-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J Immunol 1992;149:1666-70.
13. Wang A, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985;228:149-54.
14. Dealtry GB, Naylor MS, Fiers W, Balkwill FR. DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-gamma. Eur J Immunol 1987;17: 689-93.
15. Raitano AB, Scuderi P, Korc M. Long-term effect of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Int J Pancreatol 1990;6:109-18.
16. Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. Gamma-interferon plays a key role in T-cell-induced tumor regression. Cancer Res 1993;53:833-9.
17. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
18. Barth RJ, Mulsr JJ, Spiess PJ, Rosenberg SA. Interferon-gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor infiltrating lymphocytes. J Exp Med 1991;173:647-58.
19. Abbruzzese JL, Levin B, Ajani JA, et al. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Mod 1990;9:522-7.